MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/190/0.1/16.01.26 | Market Closed - Börse Stuttgart 17:07:25 06/06/2024 BST | ||
| 1.16 EUR | +5.45% |
|
| Current month | +27.47% | ||
| 1 month | +52.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 1.16 | +5.45% |
| 05/06/24 | 1.1 | +6.80% |
| 04/06/24 | 1.03 | +11.96% |
| 03/06/24 | 0.92 | +1.10% |
| 31/05/24 | 0.91 | +7.06% |
Delayed Quote Börse Stuttgart
Last update June 06, 2024 at 05:07 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME9ZMS |
| ISIN | DE000ME9ZMS4 |
| Date issued | 11/03/2024 |
| Strike | 190 $ |
| Maturity | 16/01/2026 (589 Days) |
| Parity | 10 : 1 |
| Emission price | 1.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.26 € |
|---|---|
| Lowest since issue | 0.72 € |
| Spread | 0.04 € |
| Spread % | 3.48% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
920
DKK
Spread / Average Target
-5.48%
- Stock Market
- Warrants
- Warrant